Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  Multiple Sclerosis Patients with Relapsing Remitting Multiple Sclerosis (RRMS) aged from 10 years to less than 18 years at study entry are eligible. Patients must meet the of diagnosis of Multiple Sclerosis as defined by the International Pediatric Multiple Sclerosis Study Group (IPMSSG) for pediatric Multiple Sclerosis (MS) and the of Multiple Sclerosis (MS) based on 2010 McDonald criteria Signed written informed consent/assent obtained from patient and patient's legal representative (parent or guardian) according to local regulations Expanded Disability Status Scale (EDSS) score of 0.0 to 5.0 (inclusive) at screening At least 2 recorded Multiple Sclerosis (MS) attacks and at least 1 Multiple Sclerosis (MS) attack (relapse) in the last year during treatment with a beta interferon therapy (IFNB) or glatiramer acetate (GA) after having been on that therapy for at least 6 months, and is currently still taking the same therapy At least 1 of the following new or enlarging T2 hyperintense lesion or gadolinium enhancing lesion* while on that same prior therapy (IFNB or GA), OR Two or more relapses in the prior year, OR Tried at least 2 Multiple Sclerosis Disease Modifying Therapies (DMTs)  Any progressive or non-relapsing forms of MS Conditions/situations such as Impossibility to meet specific protocol requirements Current participation in another interventional clinical study. Patients who were treated with a comparator agent approved for screening (INF or GA) may be considered for this trial Patient is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol Uncooperative patient or any condition that could make the patient potentially non-compliant to the study procedures in the opinion of the Investigator Mental condition rendering the patient or parent/guardian unable to understand the nature, scope, and possible consequences of the study Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the patient at risk by participating in the study in the opinion of the Investigator History of drug or alcohol abuse History of known human immunodeficiency virus (HIV) positivity